For providers
An editorial platform that takes women seriously.
Anthivera is the editorial publication for women researching peptide therapy. We compare providers on six published criteria, never on commercial relationships. This page is for telehealth providers who want to understand how that works — and how to be considered for a review.
The audience
Who reads Anthivera.
Audience
Women researching peptide therapy
Perimenopause, libido, skin & collagen, sleep, recovery, metabolic. High-intent, doing diligence before a first consult.
Editorial cadence
Weekly newsletter + ongoing reviews
Every provider review is dated and revisited as regulatory status changes.
What we don't do
Recommend treatment
We compare and inform. We do not recommend a specific peptide or provider for a specific medical condition.
The methodology
How we evaluate.
Six published criteria. Every review uses the same rubric. Editorial scores reflect this rubric alone — not whether a provider has any commercial relationship with the publication.
- 01
Clinician credentials
MD/DO/NP/PA presence, license verification, conditions evaluated, time-with-clinician in the actual visit.
- 02
Pharmacy sourcing
503A vs. 503B status, named pharmacy partner, ability to verify compounding source.
- 03
Pricing transparency
Posted pricing, consult fees, no surprise add-ons, refund policy.
- 04
Geographic reach
States served (with their current state of medicine), telehealth process, follow-up cadence.
- 05
Process & follow-up
Intake quality, lab handling, follow-up schedule, how the provider handles adverse events.
- 06
Women-specific care
Acknowledges perimenopause, libido, and cycle-specific considerations rather than treating women as small men.
The editorial firewall
What money can — and cannot — buy.
If we want our readers to trust us, our partners need to know exactly where the line is. It runs straight through the middle of the publication, and it does not bend.
Editorial rating is not for sale.
Our six-criteria editorial score is independent. We will never adjust it for a commercial relationship — and if we ever did, the change would be disclosed.
Sponsored placement is labeled.
If a provider is featured because of a paid relationship, you'll see a Sponsored badge. The dormant placement tier is already in our component library; it activates only on real disclosed deals.
Affiliate links are tagged.
Every outbound provider link uses rel="sponsored nofollow" and is wrapped in a tracked component. Readers always know when a link is monetized.
On the roadmap
Sponsored placement — opening in 2026.
We are not currently accepting sponsored placements. The component infrastructure — labeled Sponsored badges, disclosure language, dedicated placement tiers — is already built. When we open it, sponsored placements will be clearly labeled wherever they appear, and the editorial scorecard will remain independent.
If you are a provider who wants to be considered for editorial review now (no payment, no obligation), reach out and we will add you to the evaluation queue.